CEB-VECTRA ECG

• Research type

  Research Study

• Full title

  Utility of the Cardiac Electrical Biomarker in Patients with Ischaemic Heart Disease (Validation Study)

• IRAS ID

  202477

• Contact name

  Attila Kardos

• Contact email

  attila.kardos@mkhospital.nhs.uk

• Sponsor organisation

  Milton Keynes University Hospital NHS Foundation Trust

• Duration of Study in the UK

  3 years, 0 months, 1 days

• Research summary

  This project is aiming to identify the diagnostic utility of an ECG based Medical device (Vectraplex by VectraCor ltd) in patients who are undergoing cardiac investigations. This technology is based on the principle of vector ECG and an intelligent analyzing system that computes a composite score termed a Cardiac Electrical Biomarker (CEB TM). CEB has been validated in the detection of STEMI with high sensitivity and specificity in the detection ECG changes characteristic to STEMI. The CEB may be a more accurate way of identifying heart injury and causes of chest pain compared to standard tests, which could lead to faster diagnosis and treatment of these patients.
  We will be examining the utility of the CEB in the following:
  1. Acute chest pain assessment in the A&E department.
  2. Acute chest pain assessment in the Primary Care Surgery.
  3. Performance of CEB during inducible ischaemia in patients with stable angina
  4. Performance of CEB during acute ischaemia in patients undergoing percutaneous coronary intervention (PCI)
  5. Performance of CEB in patients undergoing cardio-toxic treatment

• REC name

  London - Surrey Research Ethics Committee

• REC reference

  16/LO/1973

• Date of REC Opinion

  30 Nov 2016

• REC opinion

  Further Information Favourable Opinion